Summary of Key Points Core Viewpoint - The company, Jiechuang Intelligent Technology Co., Ltd., is increasing its comprehensive credit limit for 2025 to support business development, with a total limit of up to RMB 600,000 million, and is accepting guarantees from related parties [1][2][6]. Group 1: Increase in Credit Limit - The company and its subsidiaries have approved a comprehensive credit limit application not exceeding RMB 300,000 million for 2025, which will be effective until the next annual shareholders' meeting [1][2]. - The total credit limit for 2025 will be increased to RMB 600,000 million, allowing for various financing activities such as working capital loans, project loans, and trade financing [2][4]. Group 2: Related Party Guarantees - The company will provide joint liability guarantees for its subsidiaries, with the actual controllers, Sun Chao, Xie Aixia, and Long Fei, also providing guarantees [2][3]. - The guarantees are classified as related transactions but do not constitute a major asset restructuring, thus requiring no additional departmental approval [3][4]. Group 3: Purpose and Impact of Related Transactions - The guarantees are intended to support the normal financing needs of the company and its subsidiaries, ensuring that daily operational funding requirements are met without negatively impacting the company's operations [4][5]. - The independent directors and audit committee have reviewed and approved the increase in credit limits, affirming that it aligns with the company's development needs and does not harm shareholder interests [5][6].

Group 1 - The company, Shanghai Kaizhong Materials Technology Co., Ltd., is issuing convertible bonds to unspecified investors, with a total face value of RMB 100.00 per bond and a maturity period of six years from August 15, 2025, to August 14, 2031 [2][3][4] - The coupon rates for the bonds are set at 0.20% for the first year, 0.40% for the second year, 0.60% for the third year, and 1.00% for the fourth year, with annual interest payments [3][4][5] - The initial conversion price for the bonds is set at RMB 12.70 per share, which will be adjusted based on specific corporate actions such as stock dividends or capital increases [5][6][7] Group 2 - The bondholders have the right to convert their bonds into shares starting from February 23, 2026, until the maturity date [4][5] - The company has provisions for redeeming the bonds at 110% of the face value plus the last year's interest within five trading days after maturity, and can also redeem the bonds under certain conditions during the conversion period [9][10] - The company will not provide any guarantees for the bonds, and the credit rating for the bonds is AA- with a stable outlook [14][15] Group 3 - The company has made changes to its corporate governance structure by abolishing the supervisory board, with the responsibilities being transferred to the audit committee of the board of directors [16][17] - These changes are in compliance with the new Company Law and are not expected to adversely affect the safety of the bondholders' principal and interest or the company's debt repayment capacity [16][17]

Core Viewpoint - The company intends to increase the use of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund utilization and maximize shareholder returns while ensuring the safety of the raised funds and the implementation of investment projects [1][5][7]. Summary by Sections Fundraising Basic Situation - The company was approved for its initial public offering (IPO) on November 27, 2020, with a total of 48.676088 million shares issued at a price of RMB 43.22 per share, raising a total of RMB 2,103.7805 million. After deducting issuance costs, the net amount raised was RMB 1,942.3216 million [1]. Fund Investment Project Basic Situation - The total planned investment for the projects funded by the raised capital is RMB 1,355.8911 million, with the same amount allocated for fundraising [2]. Previous Use of Idle Funds for Cash Management - The company previously approved the use of up to RMB 880 million of temporarily idle funds for cash management, allowing for the purchase of safe, liquid financial products. This approval is valid for 12 months from the board's decision [2][3]. Current Increase in Cash Management Usage - The company plans to increase the cash management limit by RMB 60 million, bringing the total to RMB 940 million. This increase is also valid for 12 months from the board's approval [4][6]. Investment Purpose - The aim is to rationally utilize temporarily idle funds for cash management to improve fund efficiency and increase returns for shareholders, without affecting the implementation of investment projects [3][5]. Investment Products - The company will invest in high-safety, principal-protected, and liquid products, including but not limited to guaranteed financial products, structured deposits, large certificates of deposit, and time deposits [4]. Implementation and Disclosure - The company’s chairman is authorized to make investment decisions within the approved limits, and the finance department will organize the implementation. The company will comply with relevant disclosure obligations [4][5]. Impact on the Company - The increase in cash management usage will not affect the normal operation of the company’s funds or the implementation of investment projects, and it is expected to generate additional investment returns for the company and its shareholders [5][7]. Review Procedures and Opinions - The board and supervisory committee have approved the increase in cash management usage, confirming that it aligns with legal requirements and does not harm the interests of the company or minority shareholders [6][7].

Summary of Key Points Core Viewpoint - The company is changing part of its fundraising investment projects to better align with market conditions and its strategic development needs, specifically terminating the "In Vitro Diagnostic Reagent Production Line Upgrade Project" and reallocating funds to the "Japan Intelligent Manufacturing Project" and increasing investment in the "Product R&D Project" [1][2][3]. Fundraising Investment Project Changes - The company raised a total of RMB 210,378.05 million from its initial public offering, with a net amount of RMB 194,232.16 million after deducting issuance costs [1]. - The company plans to redirect RMB 22,291.10 million from the terminated project to the new project in Japan and increase the budget for product R&D [2][4]. - The total planned investment for the projects before and after the change is as follows: - Before: RMB 135,589.11 million - After: RMB 137,426.01 million [2]. Reasons for Change - The original project was deemed less urgent due to a contraction in domestic market demand for molecular diagnostics, while the overseas market, particularly Japan, presents significant growth opportunities [4][5]. - Japan's market is characterized by high margins and strict quality standards, making it a strategic location for the company's expansion [5][6]. - The increase in the R&D budget is aimed at enhancing innovation in core technology areas, which is crucial for maintaining competitive advantage [5][6]. New Investment Project Details - The company plans to invest RMB 20,000.00 million in Japan for the construction of an intelligent production line, including land acquisition and equipment purchase [6][7]. - The project aims to leverage Japan's advanced biopharmaceutical market and enhance the company's international brand recognition [6][7][8]. Impact of Changes - The changes in fundraising project allocations are expected to improve the efficiency of fund usage and align with the company's strategic goals, without adversely affecting normal operations [8][11]. - The company has established a rigorous quality management system to ensure high standards in production and R&D processes [8].

Core Viewpoint - The company is adjusting the internal investment structure of certain fundraising projects to enhance the efficiency of fund utilization and align with its strategic development needs [1][6] Fundraising Basic Situation - The company raised a net amount of approximately RMB 746.81 million from its initial public offering (IPO) of 15 million shares at a price of RMB 131.89 million [1] Fundraising Usage Situation - As of June 30, 2025, the cumulative investment in the semiconductor testing equipment project is approximately RMB 746.81 million, with a total investment of RMB 746.81 million planned for the project [2][3] Adjustment Reasons - The adjustment is based on the evolving needs of the company due to advancements in technology and product upgrades, necessitating a reevaluation of the investment structure for the "Semiconductor Testing Equipment Intelligent Manufacturing and Innovation R&D Center Phase I Project" [4][5] Adjustment Details - The total planned investment amount remains unchanged at RMB 43.62 million, with no alteration in the project implementation entity or the total investment amount [5] Impact of Adjustment - The adjustment is expected to improve the efficiency of fund utilization and resource allocation, ensuring the smooth implementation of fundraising projects without harming the interests of the company or its shareholders [5][6] Review Procedures - The adjustment has been approved by the company's board of directors and supervisory board, following necessary review procedures [6][7]

Group 1 - The company appointed Chen Yimin as Executive Vice President and recognized Chen Guanglong as a core technical personnel on August 28, 2025 [1][2] - Chen Yimin has nearly 20 years of experience in the semiconductor industry and has held various positions within the company and its subsidiaries [1][2] - Chen Guanglong has over 20 years of experience in the semiconductor industry and has served in multiple roles, including Senior Vice President in charge of technology research and development [2][3] Group 2 - Guangping Hua will no longer serve as a core technical personnel but will remain as Executive Vice President [3] - Guangping Hua has nearly 30 years of experience in the semiconductor industry and has worked for several notable companies [3][4] - The company has established a complete R&D system and a stable team, ensuring that the personnel adjustments will not adversely affect its operational capabilities or technological advantages [4] Group 3 - The company has clear agreements regarding intellectual property, confidentiality obligations, and non-competition with Guangping Hua, ensuring no disputes regarding intellectual property ownership [4] - The addition of Chen Guanglong as a core technical personnel is expected to enhance the stability of the R&D team and maintain the company's technological competitive edge [4]

国泰海通证券股份有限公司 关于华虹半导体有限公司 与上海复旦微电子集团股份有限公司发生日常关联交易的核 查意见 国泰海通证券股份有限公司（以下简称"保荐机构"）作为华虹半导体有限公 司（以下简称"华虹公司"或"公司"）首次公开发行人民币普通股（A股）股票并 在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第11号——持 续督导》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等有 关规定，对华虹公司与上海复旦微电子集团股份有限公司（以下简称"复旦微电"） 发生日常关联交易事项进行了审慎核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司董事会于2025年8月28日就与复旦微电发生日常关联交易相关事宜作出决议， 同意公司及其合并报表范围内公司因生产经营需要，在不超过相应额度的范围内与 关联方复旦微电开展相关交易。根据《上海证券交易所科创板股票上市规则》（以 下简称"《科创板上市规则》"）的规定，公司全体独立董事同意通过上述议案。 根据《科创板上市规则》及《华虹半导体有限公司之组织 ...

Core Viewpoint - The company is extending the construction period of its fundraising project "300mm High-end Silicon Material R&D Pilot Project" to December 2026 due to delays in project implementation while maintaining the original investment direction and total amount [7][8]. Fundraising Overview - The company raised a total of RMB 4,999,999,851.17 in 2022, with a net amount of RMB 4,946,185,486.46 after deducting issuance costs [1]. - The funds are managed in a dedicated account with a tripartite supervision agreement signed with the sponsor and the supervising bank [2]. Investment Project Details - The main use of the raised funds includes the "300mm High-end Silicon Wafer R&D and Advanced Manufacturing Project" and "300mm High-end Silicon Material R&D Pilot Project" [2]. - The total investment for the "300mm High-end Silicon Material R&D Pilot Project" is RMB 214,420.80 million, with RMB 200,000 million planned from the raised funds [3]. Delay Reasons - The project has faced delays due to extended procurement cycles for key equipment, complex technology development, strict customer validation processes, and a slowdown in the semiconductor market [4][5]. Project Necessity and Feasibility - The project remains necessary and feasible as it addresses the growing demand for SOI wafers in various applications, including automotive electronics and mobile terminals [5][6]. - The company aims to fill the domestic gap in 300mm SOI wafer production, enhancing self-sufficiency in critical semiconductor materials [5]. Market Environment - The semiconductor market is recovering, driven by demand in sectors like smartphones, IoT, and AI, providing a favorable environment for the project's implementation [6]. Conclusion on Project Extension - The extension of the project timeline is a prudent decision based on actual implementation conditions and does not adversely affect the company's operations or shareholder interests [7][8].

Core Viewpoint - The report outlines the continuous supervision and guidance provided by Guotai Junan Securities for Huahai Qingke Co., Ltd. during the first half of 2025, emphasizing the company's compliance with regulations and its operational performance [2][9]. Summary by Sections Continuous Supervision Work - The sponsor has established a continuous supervision system to ensure the company adheres to regulatory obligations, including information disclosure and operational compliance [2][3]. - The sponsor has assisted the company in developing internal systems and decision-making processes to meet legal and regulatory requirements [3][4]. - The company has maintained transparency in its information disclosure, ensuring it is accurate, complete, and timely [3][4]. Financial Performance - For the first half of 2025, the company reported a revenue of approximately RMB 1.95 billion, a year-on-year increase of 30.28% [17]. - The total profit reached approximately RMB 549.78 million, reflecting an 11.66% increase compared to the previous year [17]. - The net profit attributable to shareholders was approximately RMB 505 million, marking a 16.82% increase [17]. R&D and Innovation - The company has a strong focus on R&D, with R&D expenses accounting for 12.63% of revenue, an increase from 11.72% in the previous year [17][22]. - The company has developed a robust R&D team of 722 members, representing 31.99% of its total workforce [19][20]. - The company has obtained 500 patents and 39 software copyrights, showcasing its commitment to innovation [19][20]. Risk Management - The company faces risks related to core competitiveness, including potential talent loss and technological advancements in the semiconductor equipment industry [9][10]. - The company has established a quality management system to ensure product quality and customer satisfaction [20][21]. - The company is exposed to financial risks, particularly concerning accounts receivable and customer concentration [12][13]. Use of Raised Funds - The company raised a total of RMB 364.43 million through its IPO, with a net amount of RMB 348.99 million after deducting issuance costs [2][23]. - As of June 30, 2025, the company has utilized RMB 111.58 million of the raised funds for designated projects [23]. - The company has ensured compliance with regulations regarding the management and use of raised funds [23].

Summary of Key Points Core Viewpoint - The company is utilizing its own funds to pay for investment projects and will replace these funds with raised capital, ensuring operational efficiency and compliance with regulatory requirements [1][5]. Fundraising Overview - The company raised a total of RMB 820,665.87 million by issuing 80,229,335 shares at RMB 102.29 per share, with a net amount of RMB 812,459.21 million after deducting fees [1][2]. - The total commitment for investment projects was RMB 1,000,000.00 million, with an adjusted total of RMB 811,816.24 million [2]. Investment Project Details - The main projects funded include the Micro Semiconductor Industrialization Base Construction Project (RMB 317,000.00 million) and Technology Reserve Fund (RMB 119,816.24 million) [2]. Reasons for Using Own Funds - The company used its own funds for certain project expenses due to regulatory requirements regarding employee compensation and social insurance payments, which cannot be processed through the raised capital account [2][3]. Operational Process - The company will compile a detailed list of expenses paid with its own funds, followed by a transfer of equivalent amounts from the raised capital account to its own accounts [3]. Impact on the Company - This approach is expected to enhance operational management efficiency and ensure the smooth progress of investment projects without negatively affecting normal operations [3][4]. Compliance and Approval - The decision to use own funds and replace them with raised capital has been approved by the company's board and supervisory committee, adhering to relevant regulations and internal management systems [4][5].